ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $77.71 Consensus Price Target from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have been assigned a consensus rating of "Buy" from the eight analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $77.71.

A number of brokerages recently issued reports on ANIP. Leerink Partners began coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price objective for the company. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. StockNews.com raised shares of ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 5th. HC Wainwright reissued a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Finally, Truist Financial upped their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a research note on Tuesday, October 22nd.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP traded up $0.08 during midday trading on Friday, hitting $59.00. The company had a trading volume of 24,861 shares, compared to its average volume of 178,870. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $70.81. The company has a fifty day moving average of $56.98 and a two-hundred day moving average of $58.23. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -107.74 and a beta of 0.74. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at approximately $2,943,540. This represents a 2.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Nikhil Lalwani sold 33,481 shares of the firm's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the transaction, the chief executive officer now directly owns 370,378 shares of the company's stock, valued at approximately $21,478,220.22. This trade represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 42,381 shares of company stock valued at $2,441,556. 12.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. US Bancorp DE increased its holdings in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after buying an additional 531 shares during the last quarter. KBC Group NV increased its stake in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after acquiring an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in ANI Pharmaceuticals during the fourth quarter valued at approximately $166,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock valued at $177,000 after purchasing an additional 579 shares during the period. Finally, Rafferty Asset Management LLC bought a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at approximately $200,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.